Diabetic Nephropathy – Landscape & Forecast – Disease Landscape & Forecast

Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The current standard of care fails to halt the frequent progression of DN to kidney disease and, ultimately, kidney failure—a condition associated with severe morbidity / mortality and high costs to patients and payers. As a result, key opinion leaders (KOLs) indicate that efficacious therapies for DN are a major unmet need. KOLs weigh in on the anticipated nephroprotective effects that endothelin receptor antagonists, mineralocorticoid receptor antagonists, and SGLT-2 inhibitors may offer. These therapies represent the first potentially disease-modifying therapies, should they prove efficacious and safe. The increasing prevalence of DN, exacerbated by the dynamics between clinicians seeking to prescribe new, premium-priced therapies and payers seeking to control costs among an already expensive population, will help shape the changing DN market over the next ten years.

Questions answered

  • Will the inclusion of cardiovascular endpoints in the clinical trials for select therapies be a competitive advantage once commercially available?
  • How do KOLs view the different mechanisms of action of the therapies in early- and late-phase clinical development?
  • What are the key remaining unmet needs in DN? Which drugs in development will fulfill these unmet needs?
  • What market access and reimbursement challenges will the emerging therapies face in the G7? How will these challenges influence their uptake?

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Diabetic Nephropathy - Landscape & Forecast - Disease Landscape & Forecast
    • Key Findings
      • Diabetic Nephropathy - Key Findings - January 2021
    • Key Updates
      • Q3 2021
        • September 2021
        • August 2021
        • July 2021
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q4 2020
        • December 2020
      • Q3 2020
        • July 2020
      • Q2 2020
        • April 2020
      • Q1 2020
        • March 2020
    • Market Outlook
      • Key Findings
        • Market Share of Diabetic Nephropathy Drug Classes: 2019
        • Market Share of Diabetic Nephropathy Drug Classes: 2029
        • Diabetic Nephropathy SWOT Analysis
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Diabetic Nephropathy?
        • What Factors Are Constraining the Market for Diabetic Nephropathy?
      • Drug Class-Specific Trends
        • Annual Sales of SGLT-2 Inhibitors in Diabetic Nephropathy in the United States: 2019-2029
        • Annual Patient Share of SGLT-2 Inhibitors in Diabetic Nephropathy in the United States: 2019-2029
        • Annual Sales of SGLT-2 Inhibitors in Diabetic Nephropathy in Europe: 2019-2029
        • Annual Patient Share of SGLT-2 Inhibitors in Diabetic Nephropathy in Europe: 2019-2029
        • Annual Sales of SGLT-2 Inhibitors in Diabetic Nephropathy in Japan: 2019-2029
        • Annual Patient Share of SGLT-2 Inhibitors in Diabetic Nephropathy in Japan: 2019-2029
        • Annual Sales of Antidiabetic Drug Classes in Diabetic Nephropathy in the Major Markets: 2019-2029
        • Annual Patient Share of Insulins in Diabetic Nephropathy in the Major Markets: 2019-2029
        • Annual Patient Share of Noninsulins in Diabetic Nephropathy in the Major Markets: 2019-2029
        • Annual Sales of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy in the Major Markets: 2019-2029
        • Annual Patient Share of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy in the Major Markets: 2019-2029
        • Annual Patient Share of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy in Japan: 2019-2029
        • Annual Sales of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy in Japan: 2019-2029
        • Annual Patient Share of Antihypertensive Drug Classes in Diabetic Nephropathy in the Major Markets: 2019-2029
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
        • Pathophysiology
          • Diabetic Nephropathy Pathophysiology
        • Natural History of Diabetic Nephropathy
          • Natural History
          • Stages of Natural Disease Progression: Diabetic Nephropathy
        • Risk Factors
          • Diabetic Nephropathy Risk Factors
        • Key Pathways and Drug Targets
          • Key Therapeutic Targets
      • Epidemiology
        • Key Findings
          • Epidemiology Populations
            • Disease Definition
            • Methods
            • Sources Used for Diagnosed Diabetes within Total Prevalent CKD
            • Number of Diagnosed Diabetes Within Total Prevalent CKD: 2019-2029 (Thousands)
            • Sources Used for Diagnosed Prevalence of Diabetic Nephropathy
            • Number of Diagnosed Prevalent Cases of Diabetic Nephropathy: 2019-2029 (Thousands)
        • Current Treatment
          • Key Findings
            • Treatment Goals
              • Key Endpoints Used in Clinical Trials for Diabetic Nephropathy
            • Key Current Therapies
              • Overview
              • Mechanism of Action of Key Current Drug Classes Used for Diabetic Nephropathy
              • Current Treatments Used for Glycemic Control in Diabetic Nephropathy
              • Current Treatments for Blood Pressure Control Used in Diabetic Nephropathy
              • Market Events Impacting the Use of Key Current Therapies in Diabetic Nephropathy
              • Advantages and Disadvantages of Renin-Angiotensin-Aldosterone System Inhibitors
              • Expert Insight: RAAS Inhibitors
              • Esaxerenone
              • Advantages and Disadvantages of Esaxerenone
              • Key Results from Select Clinical Trials Investigating Esaxerenone for the Treatment of Diabetic Nephropathy
              • Key Ongoing Clinical Trials of Esaxerenone in the Treatment of Diabetic Nephropathy
              • Expert Insight: Esaxerenone
              • Other Antihypertensive Drug Classes
              • Expert Insight: Other Antihypertensives Used for Diabetic Nephropathy
              • Advantages and Disadvantages of Dapagliflozin
              • Key Results from Select Clinical Trials Investigating Dapagliflozin for the Treatment of Diabetic Nephropathy
              • Expert Insight: Dapagliflozin
              • Advantages and Disadvantages of Canagliflozin
              • Key Results from Select Clinical Trials Investigating Canagliflozin for the Treatment of Diabetic Nephropathy
              • Key Ongoing Clinical Trials of Canagliflozin in the Treatment of Diabetic Nephropathy
              • Expert Insight: Canagliflozin
              • Advantages and Disadvantages of Empagliflozin
              • Key Results from Select Clinical Trials Investigating Empagliflozin for the Treatment of Diabetic Nephropathy
              • Key Ongoing Clinical Trials of Empagliflozin in the Treatment of Diabetic Nephropathy
              • Expert Insight: Empagliflozin
              • Key Results from Select Clinical Trials Investigating Ertugliflozin for the Treatment of Diabetic Nephropathy
              • Key Ongoing Clinical Trials of Ertugliflozin in the Treatment of Diabetic Nephropathy
              • Expert Insight: Ertugliflozin
              • Other Antidiabetics
              • Expert Insight: Use of Other Antidiabetics in the Treatment of Diabetic Nephropathy
            • Medical Practice
              • Overview
              • Drug Selection
              • Factors Influencing Drug Selection in Diabetic Nephropathy
              • Treatment Decision Tree for Diabetic Nephropathy: United States
              • Treatment Decision Tree for Diabetic Nephropathy: Europe
              • Treatment Decision Tree for Diabetic Nephropathy: Japan
          • Unmet Need Overview
            • Current and Future Attainment of Unmet Needs in Diabetic Nephropathy
            • Top Unmet Needs in Diabetic Nephropathy: Current and Future Attainment
            • Expert Insight: Unmet Need in Diabetic Nephropathy
          • Emerging Therapies
            • Key Findings
              • Pipeline Trends for Diabetic Nephropathy
            • Key Emerging Therapies
              • Key Emerging Therapies in Development for Diabetic Nephropathy
              • Estimated Launch Dates of Key Emerging Therapies for the Treatment of Diabetic Nephropathy
              • Likely Uses of SGLT-2 Inhibitors in the Treatment of Diabetic Patients with Renal Dysfunction
              • Key Results from Select Clinical Trials Investigating Sotagliflozin for the Treatment of Diabetic Nephropathy
              • Key Ongoing Clinical Trials of Sotagliflozin in the Treatment of Diabetic Nephropathy
              • Analysis of the Clinical Development Program for Sotagliflozin
              • Expert Insight: Sotagliflozin
              • Expectations for Launch and Sales Opportunity of Sotagliflozin in Diabetic Nephropathy
              • Key Results from Select Clinical Trials Investigating Finerenone for the Treatment of Diabetic Nephropathy
              • Analysis of the Clinical Development Program for Finerenone
              • Expectations for Market Authorization and Sales Opportunity of Finerenone in Diabetic Nephropathy
            • Early-Phase Pipeline Analysis
              • Notable Developments in the Early-Phase Pipeline for Diabetic Nephropathy / Diabetic Kidney Disease
            • Key Discontinuations and Failures in Diabetic Nephropathy
              • Key Discontinuations and Failures
          • Access & Reimbursement Overview
            • Region-Specific Reimbursement Practices
              • Key Market Access Considerations in Diabetic Nephropathy: United States
              • General Reimbursement Environment: United States
              • Key Market Access Considerations in Diabetic Nephropathy: EU5
              • General Reimbursement Environment: EU5
              • Key Market Access Considerations in Diabetic Nephropathy: Japan
              • General Reimbursement Environment: Japan
          • Appendix
            • Diabetic Nephropathy Bibliography